Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-04
2006-04-04
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S211130, C514S218000
Reexamination Certificate
active
07022700
ABSTRACT:
Compounds according to formula I:wherein R1, R2, R3, R4, R5and n are as defined herein, are administered to increase neutrophil levels in mammels.
REFERENCES:
patent: 3736315 (1973-05-01), Kórósi et al.
patent: 4322346 (1982-03-01), Kórósi et al.
patent: 4423044 (1983-12-01), Kórósi et al.
patent: 4614740 (1986-09-01), Láng et al.
patent: 4835152 (1989-05-01), Kórósi et al.
patent: 4840948 (1989-06-01), Láng et al.
patent: 5204343 (1993-04-01), Andrási et al.
patent: 5288863 (1994-02-01), Somogyi et al.
patent: 5451700 (1995-09-01), Morrissey
patent: 5459137 (1995-10-01), Andrási et al.
patent: 5519019 (1996-05-01), Andrási et al.
patent: 5521174 (1996-05-01), Andrási et al.
patent: 5639751 (1997-06-01), Andrási et al.
patent: 5891871 (1999-04-01), Xia et al.
patent: 6075018 (2000-06-01), Vágó´et al.
patent: 6080736 (2000-06-01), Landry
patent: 0 492 485 (1992-07-01), None
patent: 178516 (1983-03-01), None
patent: WO 92/11262 (1992-07-01), None
patent: WO 00/24400 (2000-05-01), None
R. J. Griffiths et al., “Leukotriene B4Plays a Critical Role in the Progression of Collagen-Induced Arthritis”, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 517-521, Jan. 1995, Medical Sciences.
F. Gatta et al., “Derivatives of 2,3-Benzodiazepine (*)”, Il Farmaco—Ed. Sc.—vol. 40—fasc. 12, pp. 942-955.
R. Sladká et al., “A Placebo-controlled Clinical Trial with Tofizopam * in the Treatment of Anxiety Neurosis” Divisions of Psychiatry, District Institutes of National Health, Prague, 2 and 4; Psychiatric Department and Psychiatric Research Unity, Medical Scholl of Charles University, Prague, Czechoslovakia, pp. 176-180.
Edit J. Horváth et al., “Anxiolytic 2,3-benzodiazepines, their Specific Binding to the Basal Ganglia”, Progress in Neurobiology vol. 60 (2000), pp. 309-342.
E. Tomori et al., “Investigation of the Metabolites of Tofizopam in Man and Animals by Gas-Liquid Chromatography-Mass Spectrometry”, Journal of Chromatography, 241 (1982), pp. 89-99.
Eva Tomori et al., “Investigation of Metabolites of Tofizopam in Man and Animals”, Polish Journal of Pharmacology and Pharmacy, 1984, 36, pp. 423-430., PL ISSN 0301-0214.
Sharon Pellow et al., “The Effects of Tofisopam, a 3,4-Benzodiazepine, in Animal Models of Anxiety, Sedation, and Convulsions”, Drug Development Research 7, pp. 61-73 (1986).
A. Bond et al., “A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam”, Fur J Clin Pharmacol (1982) 22, pp. 137-142.
B.S. Tsai et al., “The Leukotriene B4Receptor Agonist/Antagonist Activities of SC-45694 in Human Neutrophils”, The Journal of Pharmacology and Experimental Therapeutics, vol. 268, No. 3, 1994, pp. 1493-1498.
Noal Cohen et al., “Recent Progress in the Development of Leukotriene B4Antagonists”, Curr. Opin. Invest. Drugs (1994), 3(1), pp. 13-22.
J. Kanto et al., “Tofizopam: A Benzodiazepine Derivative Without Sedative Effect”, International Journal of Clinical Pharmacology, Therapy and Toxicology, vol. 20 No. 7—1982, pp. 309-312.
T. Mennini et al., “Brain Levels of Tofizopam in the Rat and Relationship with Benzodiazepine Receptors”, Naunyn-Schmiedeberg's Arch Pharmacol (1982) 321, pp. 112-115.
K. Maier et al., “The Effect of Tofisopam on Psychic Performance in Persons with More than Average Anxiety: A Controlled Experimental Trial”, Current Therapeutic Research, vol. 35, No. 4, Apr. 1984, pp. 541-548.
Chihiro Ito, Behavioral Pharmacological Study of the Structure-Activity Relationship of Benzodiazepine Derivatives—with Particular Reference to the Activity of 2,3-Benzodiazepine-, (1981) 39(3), pp. 369-384 (Japanese), pp. 1-30 (English Translation).
Milena Rizzo, “Chromatographic Separation of 2, 3-Benzodiazepines”, Journal of Chromatography B, 747 (2000), pp. 203-216.
Miklos Simonyi et al, “Stereoselective Binding of a 2,3-Benzodiazepine to Human Serum Albumin”, Biochemical Pharmacology, vol. 32, No. 12, (1983), pp. 1917-1920.
Giovambattista De Sarro et al., “GYKI 52466 and Related 2,3-Benzodiazepines as Anticonvulsant Agents in DBA/2 Mice”, European Journal of Pharmacology 294 (1995), pp. 411-422.
T. Seppälä, “Tofisopam, A Novel 3,4-Benzodiazepine: Multiple-Dose Effects on Psychomotor Skills and Memory. Comparison with Diazepam and Interactions with Ethanol”, Psychopharmacology 69, (1980), pp. 209-218.
Veijo Saano et al., “Tofizopam Modulates the Affinity of Benzodiazepine Receptors in the Rat Brain”, Pharmacology Biochemistry & Behavior, vol. 17, (1982), pp. 367-369.
Sharon Pellow et al., “The Effects of Tofisopam, a 3,4-Benzodiazepine, in Animal Models of Anxiety, Sedation, and Convulsions”, Drug Development Research 7 (1986), pp. 61-73.
A. Pakkanen et al., “Comparative Study of the Clinical Effects of Tofizopam, Nitrazepam and Placebo as Oral Premedication”, British Journal of Anacsthesics, pp. 1009-1012.
V. Saano et al., “Tofizopam Enhances the Action of Diazepam Against Tremor and Convulsions”, Medical Biology 61: (1983), pp. 49-53.
V. Saano et al., “Tofizopam Selectively Increases the Action of Anticonvulsants”, Medical Biology, 64 (1986), pp. 201-206.
S. Nicosia et al., “Leukotrienes as Mediators of Asthma”, Pulmonary Pharmacology & Therapeutics, (2001) 14, pp. 3-19.
Daniel W. Goldman et al. “Transduction by Leukotriene B4Receptors of Increases in Cytosolic Calcium in Human Polymorphonuclear Leukocytes”, vol. 35, No. 1, Jul. 1985, pp. 525-530.
Julia Visy et al., “The Role of Configuration and Conformation in the Binding of 2,3-Benzodiazepines to Human Serum Albumin”, CHIRALITY 1 (1989), pp. 271-275.
István Tarnawa et al., “Structure-Activity Relationships of 2,3-Benzodiazepine Compounds with Glutamate Antagonistic Action”, Bioorganic & Medical Chemistry Letters, vol. 3, No. 1, (1993), pp. 99-104.
Sergey V. Kalashnikov et al., “Immunomodulating Effects of Tofizopam (Grandaxin®) and Diazepam in Vitro”, Mediators of Inflammation, vol. 11, (2002), pp. 53-59.
Fogassy E. et al., “Studies on the Properties and Structure of Optically Active 1-(3,4-Dimethoxyphenyl)-4-Methyl-5-Ethyl-7,8-Dimethoxy-5H-2,3-Benzodiazepine (Tofizopam)”, Studies in Organic Chemistry, vol. 18, (1984), pp. 229-233.
K. Yamaguchi et al., “Tofisopam, A New 2,3-Benzodiazepine. Inhibition of Changes Induced by Stress Loading and Hypothalamic Stimulation”, Can. J. Physiol Pharmaco, vol. 61, (1983), pp. 619-625.
Szegó Judit et al., “Selected Passages From the Clinical-Pharmacological and Clinical Trials of Grandaxin®, ” Acta Pharmaceutica Hungarica vol. 63, (1993), pp. 91-98 (Hungarian). pp. 1-10 (English Translation).
L. Petócz et al., The Main Pharmacological Characteristics of Grandaxin (Tofizopam, Egyt-341), Hungarian Medical Journal, vol. 23, No. 4, (1975), pp. 134-138.
Petócz Luijza, “The Pharmacological Effects of Tofizopam (Grandaxin)®”, Acta Pharmaceutica Hungarica, vol. 63, (1993), pp. 79-82 (Hungarian. pp. 1-4 (English Translation).
Harris Herbert W.
Kucharik Robert F.
Drinker Biddle & Reath LLP
Monaco Daniel A.
Vela Pharmaceuticals, Inc.
Weddington Kevin E.
LandOfFree
Method of increasing neutrophil production using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of increasing neutrophil production using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of increasing neutrophil production using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605572